The FDA has?issued?a complete response letter?to Mallinckrodt’s jaundice drug stannsoporfin. Mallinckrodt plans to talk to the FDA in the coming months before deciding the fate of a drug it acquired in an $80 million buyout last year.
UK-based pharmaceutical company Mallinckrodt has entered?an agreement to acquire InfaCare Pharmaceutical and its developmental product, stannsoporfin, used for the treatment of newborns with the risk of developing severe jaundice.